Review



rabbit anti nnos  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals rabbit anti nnos
    Rabbit Anti Nnos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/pm40132240-68-19-25
    Average 93 stars, based on 21 article reviews
    rabbit anti nnos - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: G protein-coupled lactate receptor GPR81 control of ventrolateral ventromedial hypothalamic nucleus glucoregulatory neurotransmitter and 5'-AMP-activated protein kinase expression.
    Article Snippet: Astrocytes store glycogen as energy and promote neurometabolic stability through supply of oxidizable L-lactate.. Whether lactate regulates ventromedial hypothalamic nucleus (VMN) glucostatic function as a metabolic volume transmitter is unknown.. Current research investigated whether G protein-coupled lactate receptor GPR81 controls astrocyte glycogen metabolism and glucose-regulatory neurotransmission in the ventrolateral VMN (VMNvl), where glucose-regulatory neurons reside.

    Western Blot:

    Article Title: Sex-Dimorphic Octadecaneuropeptide (ODN) Regulation of Ventromedial Hypothalamic Nucleus Glucoregulatory Neuron Function and Counterregulatory Hormone Secretion
    Article Snippet: Aromatase , Novus Biologicals LLC, Centennial CO, US , NB100-1596 , AB_10000919 , WB; 1:2000 (0.5 uL/mL) , Human Aromatase protein (between residues 400-502). [UniProt# P11511] , Giles et al., Breast Cancer Res. 2018; 20(1): 50 , 29898754. .. Neuronal Nitric oxide synthase (nNOS) , Novus Biologicals , NBP1-39681 , AB_2282822 , WB; 1:1500 (0.75 uL/mL) , Human nNOS amino acids 1422-1433 (ESKKDTDEVFSS) , Mahmood et al., Mol. Cell. Neurosci. 2019; 95: 51-58 , 30660767. .. Glutamate Decarboxylase 65/67 (GAD) , Millipore Sigma, Burlington, MA, US , ABN904 , Not available , WB; 1:10000 (0.1 uL/mL) , KLH-conjugated linear peptide corresponding to 14 amino acids from the C-terminal region of human glutamate decarboxylase 2 (GAD2). , Ibrahim, et al., Brain |Res. 2019; 1711: 48-57 , 30629946.

    Article Title: Sex-dimorphic neuroestradiol regulation of ventromedial hypothalamic nucleus glucoregulatory transmitter and glycogen metabolism enzyme protein expression in the rat
    Article Snippet: Aromatase , Novus Biologicals LLC, Centennial CO, US , NB100-1596 , AB_10000919 , WB; 1:2000 (0.5 μL/mL) , Human Aromatase protein (between residues 400-502). [UniProt# P11511] , Giles et al., Breast Cancer Res. 2018; 20(1): 50 , 29898754. .. Neuronal Nitric oxide synthase (nNOS) , Novus Biologicals , NBP1-39681 , AB_2282822 , WB; 1:1500 (0.75 μL/mL) , Human nNOS amino acids 1422-1433 (ESKKDTDEVFSS) , Mahmood et al., Mol. Cell. Neurosci. 2019; 95: 51-58 , 30660767. .. Glutamate Decarboxylase 65/67 (GAD) , Millipore Sigma, Burlington, MA, US , ABN904 , Not available , WB; 1:10000 (0.1 μL/mL) , KLH-conjugated linear peptide corresponding to 14 amino acids from the C-terminal region of human glutamate decarboxylase 2 (GAD2). , Ibrahim, et al., Brain Res. 2019; 1711: 48-57 , 30629946.



    Similar Products

    rabbit anti nnos  (Novus Biologicals)
    93
    Novus Biologicals rabbit anti nnos
    Rabbit Anti Nnos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/pm40132240-68-19-25
    Average 93 stars, based on 1 article reviews
    rabbit anti nnos - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    nnos antibody  (Bio-Techne corporation)
    93
    Bio-Techne corporation nnos antibody
    Nnos Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/custom%40nbp1-39681%4011410228
    Average 93 stars, based on 1 article reviews
    nnos antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    nnos  (Novus Biologicals)
    93
    Novus Biologicals nnos
    Nnos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/pm37699381-71-74-79
    Average 93 stars, based on 1 article reviews
    nnos - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti rat nnos  (Novus Biologicals)
    93
    Novus Biologicals anti rat nnos
    Figure 4. Effects of Dbi Gene Silencing on Eu- or Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNvl Nitrergic Neurons. Groups (n = 4/group) of Dbi or SCR siRNA-pretreated, V- or INS-injected male rats were sacrificed one hour after sc injection. Individual VMNdm neuronal nitric oxide synthase <t>(nNOS/NOS1)-immunopositive</t> neurons were laser-catapult-microdissected from 10 micron-thick fresh frozen sections for multiplex single-cell qPCR analyses. Data depict mean normalized nNOS/NOS1 (Figure 4A), Gck (Figure 4B), Gkrp (Figure 4C), AMPKα1/Prkaa1 (Figure 4D), or AMPKα2/Prkaa2 (Figure 4E) mRNA measures ± S.E.M. for SCR siRNA/V (n = 8), Dbi siRNA/V (n = 8), SCR siRNA/INS (n = 8), Dbi siRNA/INS (n = 8) treatment groups. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 365.90, p < 0.001; Knockdown main effect: F(1,28): 337.27, p < 0.0001; INS main effect: F(1,28): 483.78; p < 0.001; Knockdown/INS interaction: F(1,28): 276.65; p < 0.001; Gck: F(3,28): 328.81, p < 0.001; Knockdown main effect: F(1,28): 822.64, p < 0.0001; INS main effect: F(1,28): 7.36, p = 0.011; Knockdown/INS interaction: F(1,28): 156.42, p < 0.001; Gkrp: F(3,28): 93.08, p < 0.001; Knockdown main effect: F(1,28): 173.19, p < 0.001; INS main effect: F(1,28): 92.90, p < 0.001; Knockdown/INS interaction: F(1,28): 13.14, p = 0.001; AMPKα1/Prkaa1: F(3,28): 122.73, p < 0.001; Knockdown main effect: F(1,28): 24.09, p < 0.0001; INS main effect: F(1,28): 218.50, p < 0.001; Knockdown/INS interaction: F(1,28): 125.60, p < 0.001; AMPKα2/Prkaa2: F(3,28): 160.07, p < 0.001, Knockdown main effect: F(1,28): 168.68, p < 0.0001; INS main effect: F(1,28): 121.08, p < 0.001; Knockdown/INS interaction: F(1,28): 190.44, p < 0.001. Statistical differences between discrete pairs of treatment groups are denoted as follows: *p < 0.05; **p < 0.01; and ***p < 0.001.
    Anti Rat Nnos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/pm38031405-56-58-64
    Average 93 stars, based on 1 article reviews
    anti rat nnos - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    rabbit against rat nnos  (Novus Biologicals)
    93
    Novus Biologicals rabbit against rat nnos
    Figure 4. Effects of Dbi Gene Silencing on Eu- or Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNvl Nitrergic Neurons. Groups (n = 4/group) of Dbi or SCR siRNA-pretreated, V- or INS-injected male rats were sacrificed one hour after sc injection. Individual VMNdm neuronal nitric oxide synthase <t>(nNOS/NOS1)-immunopositive</t> neurons were laser-catapult-microdissected from 10 micron-thick fresh frozen sections for multiplex single-cell qPCR analyses. Data depict mean normalized nNOS/NOS1 (Figure 4A), Gck (Figure 4B), Gkrp (Figure 4C), AMPKα1/Prkaa1 (Figure 4D), or AMPKα2/Prkaa2 (Figure 4E) mRNA measures ± S.E.M. for SCR siRNA/V (n = 8), Dbi siRNA/V (n = 8), SCR siRNA/INS (n = 8), Dbi siRNA/INS (n = 8) treatment groups. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 365.90, p < 0.001; Knockdown main effect: F(1,28): 337.27, p < 0.0001; INS main effect: F(1,28): 483.78; p < 0.001; Knockdown/INS interaction: F(1,28): 276.65; p < 0.001; Gck: F(3,28): 328.81, p < 0.001; Knockdown main effect: F(1,28): 822.64, p < 0.0001; INS main effect: F(1,28): 7.36, p = 0.011; Knockdown/INS interaction: F(1,28): 156.42, p < 0.001; Gkrp: F(3,28): 93.08, p < 0.001; Knockdown main effect: F(1,28): 173.19, p < 0.001; INS main effect: F(1,28): 92.90, p < 0.001; Knockdown/INS interaction: F(1,28): 13.14, p = 0.001; AMPKα1/Prkaa1: F(3,28): 122.73, p < 0.001; Knockdown main effect: F(1,28): 24.09, p < 0.0001; INS main effect: F(1,28): 218.50, p < 0.001; Knockdown/INS interaction: F(1,28): 125.60, p < 0.001; AMPKα2/Prkaa2: F(3,28): 160.07, p < 0.001, Knockdown main effect: F(1,28): 168.68, p < 0.0001; INS main effect: F(1,28): 121.08, p < 0.001; Knockdown/INS interaction: F(1,28): 190.44, p < 0.001. Statistical differences between discrete pairs of treatment groups are denoted as follows: *p < 0.05; **p < 0.01; and ***p < 0.001.
    Rabbit Against Rat Nnos, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/nbp1+39681/nNOS+Antibody/pm37543285-71-12-20
    Average 93 stars, based on 1 article reviews
    rabbit against rat nnos - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 4. Effects of Dbi Gene Silencing on Eu- or Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNvl Nitrergic Neurons. Groups (n = 4/group) of Dbi or SCR siRNA-pretreated, V- or INS-injected male rats were sacrificed one hour after sc injection. Individual VMNdm neuronal nitric oxide synthase (nNOS/NOS1)-immunopositive neurons were laser-catapult-microdissected from 10 micron-thick fresh frozen sections for multiplex single-cell qPCR analyses. Data depict mean normalized nNOS/NOS1 (Figure 4A), Gck (Figure 4B), Gkrp (Figure 4C), AMPKα1/Prkaa1 (Figure 4D), or AMPKα2/Prkaa2 (Figure 4E) mRNA measures ± S.E.M. for SCR siRNA/V (n = 8), Dbi siRNA/V (n = 8), SCR siRNA/INS (n = 8), Dbi siRNA/INS (n = 8) treatment groups. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 365.90, p < 0.001; Knockdown main effect: F(1,28): 337.27, p < 0.0001; INS main effect: F(1,28): 483.78; p < 0.001; Knockdown/INS interaction: F(1,28): 276.65; p < 0.001; Gck: F(3,28): 328.81, p < 0.001; Knockdown main effect: F(1,28): 822.64, p < 0.0001; INS main effect: F(1,28): 7.36, p = 0.011; Knockdown/INS interaction: F(1,28): 156.42, p < 0.001; Gkrp: F(3,28): 93.08, p < 0.001; Knockdown main effect: F(1,28): 173.19, p < 0.001; INS main effect: F(1,28): 92.90, p < 0.001; Knockdown/INS interaction: F(1,28): 13.14, p = 0.001; AMPKα1/Prkaa1: F(3,28): 122.73, p < 0.001; Knockdown main effect: F(1,28): 24.09, p < 0.0001; INS main effect: F(1,28): 218.50, p < 0.001; Knockdown/INS interaction: F(1,28): 125.60, p < 0.001; AMPKα2/Prkaa2: F(3,28): 160.07, p < 0.001, Knockdown main effect: F(1,28): 168.68, p < 0.0001; INS main effect: F(1,28): 121.08, p < 0.001; Knockdown/INS interaction: F(1,28): 190.44, p < 0.001. Statistical differences between discrete pairs of treatment groups are denoted as follows: *p < 0.05; **p < 0.01; and ***p < 0.001.

    Journal: ASN neuro

    Article Title: Diazepam Binding Inhibitor Control of Eu- and Hypoglycemic Patterns of Ventromedial Hypothalamic Nucleus Glucose-Regulatory Signaling.

    doi: 10.1177/17590914231214116

    Figure Lengend Snippet: Figure 4. Effects of Dbi Gene Silencing on Eu- or Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNvl Nitrergic Neurons. Groups (n = 4/group) of Dbi or SCR siRNA-pretreated, V- or INS-injected male rats were sacrificed one hour after sc injection. Individual VMNdm neuronal nitric oxide synthase (nNOS/NOS1)-immunopositive neurons were laser-catapult-microdissected from 10 micron-thick fresh frozen sections for multiplex single-cell qPCR analyses. Data depict mean normalized nNOS/NOS1 (Figure 4A), Gck (Figure 4B), Gkrp (Figure 4C), AMPKα1/Prkaa1 (Figure 4D), or AMPKα2/Prkaa2 (Figure 4E) mRNA measures ± S.E.M. for SCR siRNA/V (n = 8), Dbi siRNA/V (n = 8), SCR siRNA/INS (n = 8), Dbi siRNA/INS (n = 8) treatment groups. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 365.90, p < 0.001; Knockdown main effect: F(1,28): 337.27, p < 0.0001; INS main effect: F(1,28): 483.78; p < 0.001; Knockdown/INS interaction: F(1,28): 276.65; p < 0.001; Gck: F(3,28): 328.81, p < 0.001; Knockdown main effect: F(1,28): 822.64, p < 0.0001; INS main effect: F(1,28): 7.36, p = 0.011; Knockdown/INS interaction: F(1,28): 156.42, p < 0.001; Gkrp: F(3,28): 93.08, p < 0.001; Knockdown main effect: F(1,28): 173.19, p < 0.001; INS main effect: F(1,28): 92.90, p < 0.001; Knockdown/INS interaction: F(1,28): 13.14, p = 0.001; AMPKα1/Prkaa1: F(3,28): 122.73, p < 0.001; Knockdown main effect: F(1,28): 24.09, p < 0.0001; INS main effect: F(1,28): 218.50, p < 0.001; Knockdown/INS interaction: F(1,28): 125.60, p < 0.001; AMPKα2/Prkaa2: F(3,28): 160.07, p < 0.001, Knockdown main effect: F(1,28): 168.68, p < 0.0001; INS main effect: F(1,28): 121.08, p < 0.001; Knockdown/INS interaction: F(1,28): 190.44, p < 0.001. Statistical differences between discrete pairs of treatment groups are denoted as follows: *p < 0.05; **p < 0.01; and ***p < 0.001.

    Article Snippet: Briefly, after ice-cold acetone fixation (5 min), sections were blocked (1 h) with 1.5% normal goat serum (prod. no. S-1000, Vector Laboratories, Burlingame, CA, U.S.A.) in Tris-buffered saline, pH 7.4, (TBS) containing 0.05% Triton X-100 prior to incubation (36–48 h, 4°C) with rabbit anti-rat Gad65/67 (Gad; prod. no. ABN904, 1:1000; Millipore Sigma, Burlington, MA, U.S.A.; RRID: AB_2893025) or anti-rat nNOS (prod. no. NBP1-39681, 1:1000; Novus Biologicals, Littleton, CO, U.S.A.; RRID: AB_2282822) primary antibody (Bheemanapally et al., 2021; Briski et al., 2020; Roy et al., 2023; Uddin et al., 2019).

    Techniques: Marker, Gene Expression, Injection, Multiplex Assay, Knockdown

    Figure 5. Eu- versus Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNdm Nitrergic Neurons: Effects of Dbi Gene Knockdown. Experimental design, treatment group designations, target gene profiles, analytical and statistical methods, and data presentation format are identical to that described in Figure 2 above, except that nNOS-immunopositive neurons were laser-catapult-microdissected from the VMNdm. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 78.52, p < 0.001; Knockdown main effect: F(1,28): 65.83, p < 0.0001; INS main effect: F(1,28): 526.22, p < 0,001; Knockdown/INS interaction: F(1,28): 113.52, p < 0.001; Gck: F(3,28): 859.64, p < 0.001; Knockdown main effect: F(1,28): 531.39, p < 0.0001; INS main effect: F(1,28): 1197.25, p < 0.001; Knockdown/INS interaction: F(1,28): 850.27, p < 0.001; Gkrp: F(3,28): 14.82, p < 0.001; Knockdown main effect: F(1,28): 1.04, p = 0.317; INS main effect: F(1,28):4.44, p = 0.044; Knockdown/INS interaction: F(1,28): 38.99, p < 0.001; AMPKα1/Prkaa1: F(3,28): 39.14, p < 0.001; Knockdown main effect: F(1,28): 14.03, p = 0.001; INS main effect: F(1,28): 20.78, p < 0,001; Knockdown/INS interaction: F(1,28): 82.60, p < 0.001; AMPKα2/ Prkaa2: F(3,28): 88.86, p < 0.001; Knockdown main effect: F(1,28): 46.27, p < 0.0001; INS main effect: F(1,28): 183.48, p < 0.001; Knockdown/INS interaction: F(1,28): 36.81, p < 0.001. *p < 0.05, **p < 0.01, and ***p < 0.001.

    Journal: ASN neuro

    Article Title: Diazepam Binding Inhibitor Control of Eu- and Hypoglycemic Patterns of Ventromedial Hypothalamic Nucleus Glucose-Regulatory Signaling.

    doi: 10.1177/17590914231214116

    Figure Lengend Snippet: Figure 5. Eu- versus Hypoglycemic Neurotransmitter and Metabolic Sensor Marker Gene Expression Patterns in VMNdm Nitrergic Neurons: Effects of Dbi Gene Knockdown. Experimental design, treatment group designations, target gene profiles, analytical and statistical methods, and data presentation format are identical to that described in Figure 2 above, except that nNOS-immunopositive neurons were laser-catapult-microdissected from the VMNdm. Outcomes of statistical analyses are as follows: nNOS: F(3,28): 78.52, p < 0.001; Knockdown main effect: F(1,28): 65.83, p < 0.0001; INS main effect: F(1,28): 526.22, p < 0,001; Knockdown/INS interaction: F(1,28): 113.52, p < 0.001; Gck: F(3,28): 859.64, p < 0.001; Knockdown main effect: F(1,28): 531.39, p < 0.0001; INS main effect: F(1,28): 1197.25, p < 0.001; Knockdown/INS interaction: F(1,28): 850.27, p < 0.001; Gkrp: F(3,28): 14.82, p < 0.001; Knockdown main effect: F(1,28): 1.04, p = 0.317; INS main effect: F(1,28):4.44, p = 0.044; Knockdown/INS interaction: F(1,28): 38.99, p < 0.001; AMPKα1/Prkaa1: F(3,28): 39.14, p < 0.001; Knockdown main effect: F(1,28): 14.03, p = 0.001; INS main effect: F(1,28): 20.78, p < 0,001; Knockdown/INS interaction: F(1,28): 82.60, p < 0.001; AMPKα2/ Prkaa2: F(3,28): 88.86, p < 0.001; Knockdown main effect: F(1,28): 46.27, p < 0.0001; INS main effect: F(1,28): 183.48, p < 0.001; Knockdown/INS interaction: F(1,28): 36.81, p < 0.001. *p < 0.05, **p < 0.01, and ***p < 0.001.

    Article Snippet: Briefly, after ice-cold acetone fixation (5 min), sections were blocked (1 h) with 1.5% normal goat serum (prod. no. S-1000, Vector Laboratories, Burlingame, CA, U.S.A.) in Tris-buffered saline, pH 7.4, (TBS) containing 0.05% Triton X-100 prior to incubation (36–48 h, 4°C) with rabbit anti-rat Gad65/67 (Gad; prod. no. ABN904, 1:1000; Millipore Sigma, Burlington, MA, U.S.A.; RRID: AB_2893025) or anti-rat nNOS (prod. no. NBP1-39681, 1:1000; Novus Biologicals, Littleton, CO, U.S.A.; RRID: AB_2282822) primary antibody (Bheemanapally et al., 2021; Briski et al., 2020; Roy et al., 2023; Uddin et al., 2019).

    Techniques: Marker, Gene Expression, Knockdown